TD Asset Management Inc Sells 144,418 Shares of Ionis Pharmaceuticals, Inc. $IONS

TD Asset Management Inc lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 13.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 960,272 shares of the company’s stock after selling 144,418 shares during the period. TD Asset Management Inc owned approximately 0.59% of Ionis Pharmaceuticals worth $62,821,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of IONS. Dana Investment Advisors Inc. bought a new stake in shares of Ionis Pharmaceuticals during the third quarter worth approximately $1,231,000. OneDigital Investment Advisors LLC bought a new position in shares of Ionis Pharmaceuticals during the third quarter worth approximately $235,000. Hillsdale Investment Management Inc. acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth approximately $4,638,000. GSA Capital Partners LLP acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth approximately $665,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in Ionis Pharmaceuticals by 161.3% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 155,790 shares of the company’s stock worth $10,192,000 after purchasing an additional 96,164 shares during the last quarter. 93.86% of the stock is owned by institutional investors.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 15,642 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $81.76, for a total transaction of $1,278,889.92. Following the completion of the sale, the executive vice president directly owned 32,105 shares in the company, valued at $2,624,904.80. This represents a 32.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brett P. Monia sold 29,430 shares of the firm’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $85.79, for a total value of $2,524,799.70. Following the completion of the sale, the chief executive officer directly owned 254,497 shares in the company, valued at approximately $21,833,297.63. This represents a 10.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 464,579 shares of company stock worth $37,630,193 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ IONS opened at $80.60 on Friday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 2.78 and a current ratio of 2.79. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.74. The stock has a market capitalization of $13.05 billion, a P/E ratio of -33.03 and a beta of 0.29. The stock’s fifty day moving average is $81.30 and its 200 day moving average is $71.63.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.18). The firm had revenue of $203.00 million for the quarter, compared to the consensus estimate of $156.07 million. Ionis Pharmaceuticals had a negative return on equity of 66.25% and a negative net margin of 40.36%.The company’s revenue for the quarter was down 10.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.66) EPS. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Ionis Pharmaceuticals News Roundup

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat estimates — quarterly revenue came in around $203M, helped by strong Tryngolza sales, showing commercial traction for the lead product. Ionis Q4 Earnings & Sales Beat
• Neutral Sentiment: Analyst note: Stifel nudged its price target higher to $77 and maintained a Hold — a modest vote of confidence but the target still sits below the stock’s recent trade, so it’s not a bullish catalyst. Benzinga: Stifel Price Target
• Neutral Sentiment: Management outreach — Ionis presented at the Oppenheimer Healthcare Life Sciences conference and posted its Q4 earnings call transcript and slide deck, giving investors more detail on commercialization plans and pipeline milestones. Useful for diligence but not immediately market‑moving. Oppenheimer Conference Transcript
• Negative Sentiment: Soft FY‑2026 revenue guidance — Ionis guided revenue of $800–$825M, well below the street (~$895.6M). Management flagged slower uptake for some newer drugs, which put pressure on the stock despite the quarter’s revenue beat. Ionis Guides Below 2026 Sales Views
• Negative Sentiment: Profitability/EPS confusion and misses — headlines show mixed EPS outcomes (company reported an adjusted loss in the quarter with some outlets noting an EPS miss vs. consensus), which combined with the weak guide increased uncertainty on near‑term earnings power. Press Release / Slide Deck

Wall Street Analyst Weigh In

IONS has been the topic of a number of research reports. Leerink Partners upped their price objective on Ionis Pharmaceuticals from $85.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Wall Street Zen cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. HC Wainwright upped their price target on shares of Ionis Pharmaceuticals from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Piper Sandler raised their price target on shares of Ionis Pharmaceuticals from $77.00 to $87.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $89.00 price objective (up from $85.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $88.15.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.